<DOC>
	<DOCNO>NCT03031249</DOCNO>
	<brief_summary>In open-label , randomize , prospective clinical trial , nucleophosmin-1 ( NPM1 ) mutate acute myeloid leukemia ( AML ) patient reach CR randomize two groups.The control group receive high-dose cytarabine ( HDAC ) regimen experimental group receive high dose cytarabine plus tretinoin ( ATRA ) arsenic trioxide ( ATO ) treatment.The safety efficacy ATRA ATO evaluate .</brief_summary>
	<brief_title>Efficacy Safety ATO Plus ATRA Nucleophosmin-1 Mutated Acute Myeloid Leukemia</brief_title>
	<detailed_description>In open-label , randomize , prospective clinical trial , NPM1- mutate AML patient reach CR randomize two group . In experimental group , patient receive cytarabine dose 3g/㎡/d first , third fifth day , ATRA dose 30mg/㎡/d day 1-14 ATO dose 0.15mg/kg/d ( maximum , 10mg/d ) day 1-14 . Patients control group receive high dose cytarabine . The safety efficacy ATRA plus ATO regimen evaluated.The primary outcome relapse-free survival rate treatment .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>1 . Age 14 55 year old ; 2 . Patients meet diagnostic criterion ( WHO 2008 criterion ) AML ( except APL subtypes ) NPM1mutated . 3 . Reached CR induction regimen . 4 . ECOG score ≤ 2 ; 5 . Patients eligible laboratory examination include liver , renal heart function . 6 . Adult patient willing participate study sign inform consent immediate family . Patients 18 year old willing participate legal guardian sign inform consent . 1 . Secondary leukemia . 2 . Patients tumor active stage receive radiotherapy chemotherapy last 6 month due tumor . 3 . Patients blood disease ( example , haemophiliac ) excluded.However , patient abnormal blood count , undiagnosed MDS MPD patient include . 4 . Acute panmyelosis myelofibrosis myeloid sarcoma patient ; 5 . With BCRABL fusion gene ; 6 . Pregnant lactating woman ; 7 . With ineligible renal liver function ; 8 . With active cardiovascular disease ; 9 . Severe infection disease include uncured tuberculosis pulmonary aspergillosis ; 10 . AIDS ; 11 . Patients central nervous system involvement diagnose AML . 12 . Patients epilepsy dementia mental disease could n't understand follow research . 13 . Drugs , medical , mental social situation may distract patient follow research evaluate result . 14 . Patients factor consider unsuitable participate study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>